Poster fra Sloan-Kettering studie presentert på Neuroblastoma forskningskonferanse i Koyoto
Published 28.05.2008
Det vises til børsmelding fra selskapet av 16. januar i år om mottatt klinisk studierapport fra kreftstudie ved Memorial Sloan-Kettering Cancer Center i USA. I studien inngår SBG....
Biotec Pharmacon har mottatt klinisk studierapport fra kreftstudien ved Memorial Sloan-Kettering Cancer Center. I denne studien, som er en fase I/II sikkerhetsstudie, har SBG blitt...
Biotec Pharmacon ASA har inngått den første større leveranseavtalen for Cod Uracil-DNA-glycosylase (Cod UNG). Avtalen er inngått med en ledende internasjonal leverandør av biotekno...
PRELIMINARY RESULTS FROM THE SLOAN-KETTERING CLINICAL STUDY
Published 29.06.2007
Preliminary results from the immunotherapeutic cancer study at Memorial Sloan-Kettering Cancer Center show a very good safety profile for SBG. Furthermore, encouraging responses on...
Biotec Pharmacon ASA has after close of business at Oslo Stock Exchange on June 20th, 2007, completed a share issue of 2,148,900 new shares to a price of NOK 43 per share. The Comp...
Biotec Pharmacon announced on June 11th 2007 that the European Medicines Agency (“EMEA”) had confirmed that the company may be in a position to file for marketing authorization bas...
BIOTEC PHARMACON ENTERS PHASE III WITH THE DIABETIC ULCERS INDICATION
Published 11.06.2007
Biotec Pharmacon has during the past several months cooperated with and obtained scientific advice from the European Medicines Agency (EMEA) regarding the clinical development prog...
BIOTEC PHARMACON ENTERS PHASE III WITH THE ORAL MUCOSITIS INDICATION
Published 11.06.2007
Biotec Pharmacon has during the past several months cooperated with and obtained scientific advise from the European Medicines Agency (EMEA) regarding the clinical development prog...
Poster presentation at CHI's 3rd annual qPCR conference
Published 22.03.2007
New data on the use of Cod UNG for contamination control in qRT-PCR has been presented at Cambridge Healthtech Institute's 3rd Annual qPCR conference in San Diego 19-21 March...
